Is It Safe to Restart Antivascular Endothelial Growth Factor Therapy in Patients with Renal Cell Carcinoma after Cardiac Ischemia?
| Autor: | Brian I. Rini, Karen B. James, Laura S. Wood, Bo Zhao |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Oncology
medicine.medical_specialty medicine.medical_treatment Case Report Disease urologic and male genital diseases Bioinformatics lcsh:RC254-282 chemistry.chemical_compound Renal cell carcinoma Internal medicine medicine In patient business.industry Cardiac ischemia Sunitinib Growth factor lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens medicine.disease female genital diseases and pregnancy complications Axitinib Vascular endothelial growth factor chemistry cardiovascular system business medicine.drug |
| Zdroj: | Case Reports in Oncological Medicine Case Reports in Oncological Medicine, Vol 2015 (2015) |
| ISSN: | 2090-6714 2090-6706 |
| DOI: | 10.1155/2015/817578 |
| Popis: | Agents targeting vascular endothelial growth factor (VEGF) represent active drugs in treating patients with advanced renal cell carcinoma (RCC). Studies have shown that sunitinib and axitinib can be associated with cardiac toxicity. Whether these agents should be restarted in patients who experience cardiac ischemia remains uncertain. Here, we present three patients with metastatic RCC who restarted sunitinib or axitinib after intervention of active ischemic cardiac disease without causing subsequent relevant cardiac events. This experience suggests that these agents can be continued after management of cardiac ischemia. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|